Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
EGFR mutation
i
Other names:
EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
1956
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Related tests:
Oncomine™ Dx Target Test (10)
Idylla™ EGFR Mutation Test
Lung Cancer 8-Gene Kit
Oncomine™ Dx Target Test (10)
Idylla™ EGFR Mutation Test
Lung Cancer 8-Gene Kit
Associations
(196)
News
Trials
Search handles
@ADesaiMD
@APassaroMD
@AdnanNagrial
@AnaVManana
@AncelJulienMD
@AndresFCardonaZ
@BenjaminBesseMD
@BiagioMd
@BijoyTelivala
@BoschBarrera
@BrendonStilesMD
@BrunaPellini
@CAudigierValett
@CarlesEscriu
@CharuAggarwalMD
@ChristianRolfo
@ClaudioVladmir
@DevikaDasMD
@DocMCotant
@DoctorJSpicer
@DrBivas
@DrChoueiri
@DrHealeyBird
@DrJNaidoo
@DrMarkAwad
@DrR_DUNNE
@DrSanjayPopat
@DrSteveMartin
@DrVijayPatil11
@DrViteri
@Dr_Ivanoncologo
@Dr_R_Kurzrock
@EladSharonMD
@FawziAbuRous
@FordePatrick
@GRecondoMD
@GautschiOliver
@Geeky_Foodie
@GlopesMd
@HHorinouchi
@HenningWillers
@IyengarPuneeth
@JackWestMD
@Jbauml
@JessicaJLinMD
@JordiRemon
@Joshua_Reuss
@JulienMazieres
@Kristel_GT
@Latinamd
@LeXiuning
@LeciaSequist
@LuisERaez1
@LuisLara_M
@LungCancerDr
@MLPOncoData
@MPishvaian
@MarieWislez
@MartinReck2
@Mat_Guc
@NormandBlais
@OncoLucus
@PamelaKunzMD
@PatelOncology
@PatrickCMa1
@RManochakian
@RenoHemonc
@RielyMD
@SKabrajiMD
@SalemGIOncDoc
@SantiCabezas1
@ShaalanBeg
@ShrutiPatelMD
@StephenVLiu
@SuyogCancer
@SyedMAhmedMDPhD
@TiansterZhang
@TommyJohn00
@Tony_Calles
@VamsiVelcheti
@VincentRK
@VivekSubbiah
@YasarHammor
@aakonc
@abraocantoMD
@aftimosp
@antonyruggeri
@bmassutis
@bpiperdi
@bpshah79
@cczielinski
@cdanicas
@christine_lovly
@chulkimMD
@cinthiavgauna
@collin_blakely
@diegoadiazg
@dipeshuprety4
@dplanchard
@dr_yakupergun
@drcbsteer
@drgandara
@drkpavithran
@esinghimd
@g_mountzios
@herbloong
@ipreeshagul
@jonathanloree
@jsoriamd
@lindamahj
@malkadav
@mlazqui
@mtmdphd
@n8pennell
@ns_chd
@oncologician
@pashtoonkasi
@ravikanesvaran
@rdoebele
@rsm2800
@ryangentzler
@saadvikdr
@smitha42
@tehfem
@theabzlab
@trnsltnl
@wangyub
@weldeiry
@weoncologists
@yekeduz_emre
Search handles
@ADesaiMD
@APassaroMD
@AdnanNagrial
@AnaVManana
@AncelJulienMD
@AndresFCardonaZ
@BenjaminBesseMD
@BiagioMd
@BijoyTelivala
@BoschBarrera
@BrendonStilesMD
@BrunaPellini
@CAudigierValett
@CarlesEscriu
@CharuAggarwalMD
@ChristianRolfo
@ClaudioVladmir
@DevikaDasMD
@DocMCotant
@DoctorJSpicer
@DrBivas
@DrChoueiri
@DrHealeyBird
@DrJNaidoo
@DrMarkAwad
@DrR_DUNNE
@DrSanjayPopat
@DrSteveMartin
@DrVijayPatil11
@DrViteri
@Dr_Ivanoncologo
@Dr_R_Kurzrock
@EladSharonMD
@FawziAbuRous
@FordePatrick
@GRecondoMD
@GautschiOliver
@Geeky_Foodie
@GlopesMd
@HHorinouchi
@HenningWillers
@IyengarPuneeth
@JackWestMD
@Jbauml
@JessicaJLinMD
@JordiRemon
@Joshua_Reuss
@JulienMazieres
@Kristel_GT
@Latinamd
@LeXiuning
@LeciaSequist
@LuisERaez1
@LuisLara_M
@LungCancerDr
@MLPOncoData
@MPishvaian
@MarieWislez
@MartinReck2
@Mat_Guc
@NormandBlais
@OncoLucus
@PamelaKunzMD
@PatelOncology
@PatrickCMa1
@RManochakian
@RenoHemonc
@RielyMD
@SKabrajiMD
@SalemGIOncDoc
@SantiCabezas1
@ShaalanBeg
@ShrutiPatelMD
@StephenVLiu
@SuyogCancer
@SyedMAhmedMDPhD
@TiansterZhang
@TommyJohn00
@Tony_Calles
@VamsiVelcheti
@VincentRK
@VivekSubbiah
@YasarHammor
@aakonc
@abraocantoMD
@aftimosp
@antonyruggeri
@bmassutis
@bpiperdi
@bpshah79
@cczielinski
@cdanicas
@christine_lovly
@chulkimMD
@cinthiavgauna
@collin_blakely
@diegoadiazg
@dipeshuprety4
@dplanchard
@dr_yakupergun
@drcbsteer
@drgandara
@drkpavithran
@esinghimd
@g_mountzios
@herbloong
@ipreeshagul
@jonathanloree
@jsoriamd
@lindamahj
@malkadav
@mlazqui
@mtmdphd
@n8pennell
@ns_chd
@oncologician
@pashtoonkasi
@ravikanesvaran
@rdoebele
@rsm2800
@ryangentzler
@saadvikdr
@smitha42
@tehfem
@theabzlab
@trnsltnl
@wangyub
@weldeiry
@weoncologists
@yekeduz_emre
Filter by
Latest
8ms
WATCH: Expert oncologists reflect on the state of molecular testing in NSCLC and how it informs the management of patients with uncommon EGFR mutations. @benlevylungdoc @hopkinskimmel @UMiamiHealth #lungcancer https://t.co/vp5pIxGdHx (@OncLive)
8 months ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
8ms
In #clinicaltrial EA5161, investigators at are testing a new treatment approach for patients with #NSCLC w/ EGFR ex20-ins mutations. For more: https://t.co/pwy12PyvBr cc: @ZPiotrowskaMD, @LeciaSequist (@eaonc)
8 months ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
8ms
#Clinicaltrial EA5162, led by @ZPiotrowskaMD and @LeciaSequist of @MGHCancerCenter, will evaluate how well osimertinib works in treating pts w/ advanced #NSCLC w/ EGFR ex20-ins mutations. Learn more here: https://t.co/pwy12PyvBr #lcsm (@eaonc)
8 months ago
Clinical • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Tagrisso (osimertinib)
8ms
Delighted to share our latest paper on the mechanistic modeling of disease progression in EGFR-mutant lung adenocarcinoma: https://t.co/dsB0zfo9rc A special thanks to @MDuruisseaux & to all co-authors from @novadiscovery , @JanssenFRA. (@Claudio_MonT_s)
8 months ago
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
8ms
Join us for this fun + inspiring “thinktank” to study #EGFR-mutant #lungcancer with a great community! Meet the incredible @jillfeldman4 + @ivybelkins! Link for abstract submission below. Deadline 8/18. #hemeoncfellows @OncoAlert #LCSM @EGFRResisters @EGFRSummit https://t.co/SiobKVyQKA (@christine_lovly)
8 months ago
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
8ms
“Adjuvant Osimertinib Improves Overall Survival in EGFR-Mutated Lung Cancer” presented by Dr Roy S. Herbst and colleagues at the 2023 ASCO Annual Meeting https://t.co/gK0miTQZc6 @DrRoyHerbstYale @ASCO #ASCO23 (@clinadvances)
8 months ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Tagrisso (osimertinib)
8ms
A multiD intervention (radiology, pathology, pharmacy, & oncology) ⬇️⬇️ time to start osimertinib for pts with #EGFR-mutant #NSCLC (5 vs 23 days) by directly analyzing frozen tissue & engaging pharmacy early: https://t.co/FHkNGChqVK #LungCancer #lcsm @IbiayiMD (@JCOOP_ASCO)
8 months ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Tagrisso (osimertinib)
8ms
#Clinicaltrial EA5162, led by @ZPiotrowskaMD and @LeciaSequist of @MGHCancerCenter, will evaluate how well osimertinib works in treating pts w/ advanced #NSCLC w/ EGFR ex20-ins mutations. Learn more here: https://t.co/pwy12PyvBr #lcsm (@eaonc)
8 months ago
Clinical • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Tagrisso (osimertinib)
8ms
Honored to write an invited editorial on "Zipalertinib in EGFR Exon 20–Mutant NSCLC" - out now in @JCO_ASCO @ASCO @StephenVLiu - we discuss the role of novel TKIs, and drug development in this rare, but increasingly crowded space! Congrats to the authors on this important… https://t.co/q2gu83PHLN (@CharuAggarwalMD)
8 months ago
EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
zipalertinib (CLN-081)
8ms
A targeted therapy drug improved survival in pts w/ #lungcancer who have #EGFR mutations. PC3I's @CharuAggarwalMD provided input for @theNCI: “This confirms our practice to test for EGFR mutations and recommend adjuvant targeted therapy with osimertinib” https://t.co/O3AdUxmIdX (@PC3Innovation)
8 months ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Tagrisso (osimertinib)
9ms
Also, I don’t think supportive care docs necessarily know the scope of therapeutic options or outcomes and they are sometimes “brought in” to get pts into hospice. PS3 with stage IV pancreatic cancer is very different than PS3 with untreated EGFR mutant lung cancer. (@Alexmenter)
9 months ago
Clinical • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
9ms
Yeah I think oncology gets very nuanced and we don’t expect internists to know this stuff. For example metastatic breast cancer sounds terrible. But with hormonal therapies patients can often live many years with good QOL. Same with EGFR mutated metastatic NSCLC (@INizMD)
9 months ago
Clinical • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
9ms
Brilliant overview from biology to trials from @RamalingamMD @WinshipAtEmory on EGFR mutant refractory #lungcancer — great objectives to improve IO therapies for NSCLC in their SPORE program. #Pitt23 @UPMC @UPMCHillmanCC (@TiansterZhang)
9 months ago
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
9ms
Dr. @ipreeshagul presenting EGFR Mutations in Advanced #NSCLC. #TargetedTherapiesInLungCancer #LungCancer #CancerEducation #cancerGRACE (@cancerGRACE)
9 months ago
Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
9ms
Dr. @ipreeshagul is a dynamic ⭐️ speaker - a comprehensive, to-the-point review of current treatment landscape in EGFR-mutated NSCLC including the latest ASCO updates, at Targeted Therapies Forum 2023 @cancergrace (@JessicaJLinMD)
9 months ago
Review
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
9ms
@teekayowo gives a poignant introduction and gift for @RamalingamMD @WinshipAtEmory, “who we want to be when we grow up” — giving keynote talk on treatment in refractory EGFR mutant lung cancer #Pitt23 @UPMC @UPMCHillmanCC (@TiansterZhang)
9 months ago
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
9ms
MET positivity showed predictive value for durable responses with amivantamab plus lazertinib in patients with EGFR-mutated NSCLC whose disease progressed on/after osimertinib and are chemotherapy naïve. @BenjaminBesseMD @GustaveRoussy @ASCO #ASCO23 #lcsm https://t.co/UHG7PDlrer (@OncLive)
9 months ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Tagrisso (osimertinib) • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
9ms
Latest living guideline update on stage IV NSCLC just published. Listen to Dr. @ns_chd share the new updates - including second-line options for patients with EGFR exon 20 insertions or KRAS G12C mutations - & the rationale in our latest podcast episode https://t.co/yIzwf6akKb (@BrittanyEHarvey)
9 months ago
Clinical • EGFR exon 20 • Metastases
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • EGFR mutation • KRAS G12C • EGFR exon 20 insertion • KRAS G12 • EGFR exon 20 mutation
9ms
Cemiplimab is an immunotherapy drug used to treat advanced non-small cell lung cancer (NSCLC). ROS1 fusion is a genetic variant in NSCLC, while EGFR mutation and ALK fusion are two other common NSCLC genetic variants. (@forista8)
9 months ago
IO biomarker • Metastases
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • ALK fusion • ROS1 fusion
|
Libtayo (cemiplimab-rwlc)
9ms
1. First in man study of gleevec in CML. 2. Discovery of EGFR mutations in patients who respond to gefitinib. 3. Whole genome sequencing of the first AML genome. (@rosslevinemd)
9 months ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
gefitinib • imatinib
9ms
WATCH: Benjamin Besse, MD, PhD, discuss the biomarker analysis of the phase 1/1b CHRYSALIS-2 study of amivantamab & lazertinib in EGFR-mutated #NSCLC. #lcsm | @BenjaminBesseMD @GustaveRoussy https://t.co/HefAm5R0C8 (@TargetedOnc)
9 months ago
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
9ms
New in #JIPO "Optimizing the Treatment for Advanced Non–Small-Cell Lung Cancer with Mutated Epidermal Growth Factor Receptor in Low-Income Countries, A Review" by Drs Alali and Saifo https://t.co/DOQ79Op0Bj #lungcancer @MousaMAlali @ANaingMD @weoncologists @OncologyNetwork (@JIPOEditors)
9 months ago
Review • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
9ms
Case report of a patient with #EGFR mutant NSCLC who developed an acquired #BRAF V600E mutation on osimertinib as well as leptomeningeal disease and achieved durable control with osimertinib, dabrafenib, and trametinib. #JTOCRR @JTOonline https://t.co/TcycKvLI9x (@StephenVLiu)
9 months ago
Clinical
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene)
|
BRAF V600E • EGFR mutation • BRAF V600
|
Mekinist (trametinib) • Tagrisso (osimertinib) • Tafinlar (dabrafenib)
9ms
Befotertinib another third gneration agent in EGFR mutated NSCLC @Bhosale26Bharat @AshayKarpe59998 @Nandinimenon18 https://t.co/1B3U8IKTTd (@DrVijayPatil11)
9 months ago
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Semena (befotertinib)
9ms
First line treatment patterns for patients with EGFR mutant lung cancer in #LATAM #lcsm with @GlopesMd @CPupareli Dr. William William & Jeronimo Rodriguez Cid (@GRecondoMD)
9 months ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
9ms
What is the role of immunotherapy alone or in combination in patients with EGFR mutant lung cancer? Great debate in #LATAMoncologySummit @ClaudioVladmir @GlopesMd @JorgeAlatorreA1 💡 (@GRecondoMD)
9 months ago
Clinical • IO biomarker
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
9ms
The "Lazarus Response" in Treatment-Naive, Poor Performance Status Patients With Non-Small-Cell Lung Cancer and Epidermal Growth Factor Receptor Mutation by @coreylangermd #TBT https://t.co/VddAGIsLyd (@ASCOBuzz)
9 months ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
9ms
Benjamin Besse, MD, PhD, discussed phase 1/1b CHRYSALIS-2 data of amivantamab + lazertinib in EGFR-mutated #NSCLC. #lcsm | @BenjaminBesseMD @GustaveRoussy https://t.co/zlllgfab3r (@TargetedOnc)
9 months ago
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
9ms
Lazertinib vs Gefitinib as First-line Treatment in Patients with EGFR-mutated advanced NSCLC: LASER301 Lazertinib vs Gefitinib mPFS➡️20.6 vs 9.7 mo ORR➡️76% vs 76% mDOR➡️19.4 vs 8.3 mo 18-m OS➡️80% vs 72% @JCO_ASCO @OncoAlert https://t.co/62K6Lo7F2q (@dr_yakupergun)
9 months ago
Clinical • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
gefitinib • Leclaza (lazertinib)
9ms
Excited to share our case reports detailing various therapeutic strategies for overcoming EGFR mutations as acquired resistance mechanisms in ALK NSCLC just published in @FrontOncology ⬇️⬇️ #LionelMichaux 👏 @CadranelJ https://t.co/ImlKqSNwm6 (@FalletVincent)
9 months ago
Clinical
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation
9ms
Are you ready for targeted neoadjuvant therapy for EGFR and KRAS G12C mutant NSCLC? @MNagasaka and @kamarroneMD discuss ongoing trials with these new treatment paradigms. More discussion to come later in the program! #DAVAHawaiiLung https://t.co/CSNPUHba3j (@KE_Gallaway)
9 months ago
Clinical
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • EGFR mutation • KRAS G12C • KRAS G12
9ms
WATCH: Benjamin Besse, MD, PhD, discusses the main findings of the phase 1/1b CHRYSALIS-2 study in EGFR-mutated #NSCLC. @BenjaminBesseMD @GustaveRoussy https://t.co/g7owFprw5y (@TargetedOnc)
9 months ago
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
9ms
#FeatureFriday Today on #FeatureFriday, we are featuring a tweet by Dr. Tejas Patil [@TejasPatilMD] highlighting the importance of comprehensive #NGS and the limitation of PCR assays in the detection of #EGFR mutations in #NSCLC. #MedTwitter (@4baseCare)
9 months ago
Next-generation sequencing
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
9ms
#ILCC23 what to do at the time of PD from acquired resistance in oncogene-driven NSCLC? Empiric or biomarker-related decision making? Is paradigm different for EGFR-mutated vs ALK vs METex14 vs KRAS G12C? Come listen to our panel discussion @HwakeleeMD @DrRoyHerbstYale @gotoPER (@drgandara)
9 months ago
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase)
|
KRAS mutation • EGFR mutation • KRAS G12C • KRAS G12
10ms
New in #JIPO "Optimizing the Treatment for Advanced Non–Small-Cell Lung Cancer with Mutated Epidermal Growth Factor Receptor in Low-Income Countries, A Review" by Drs Alali and Saifo https://t.co/DOQ79Op0Bj #lungcancer @MousaMAlali @ANaingMD @weoncologists @OncologyNetwork (@JIPOEditors)
10 months ago
Review • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
10ms
At #ASCO23, @DrRoyHerbstYale presented overall survival data for adjuvant osimertinib in resected, EGFR-mutated NSCLC. Read a recap in #ILCN: https://t.co/b40STpBg2f #LCSM (@IASLC)
10 months ago
Clinical
|
EGFR (Epidermal growth factor receptor) • TPBG (Trophoblast Glycoprotein)
|
EGFR mutation
|
Tagrisso (osimertinib)
10ms
@jillfeldman4 & I just finished taping: “EGFR mutations are not all the same: the importance of biomarker testing in non-small cell lung cancer (NSCLC)—a podcast discussion between patients and oncologists” w/Drs. Sarah Goldberg and @StephenVLiu. Stay tuned @EGFRResisters! #lcsm (@ivybelkins)
10 months ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
10ms
My answer would be no. I dont think we have enough data but retrospective evidence suggests patients EGFR-mutated NSCLC do not benefit with consolidation durvalumab and experienced a high frequency of irAEs. https://t.co/Pa5skwPQe8 (@TkarawadiaMD)
10 months ago
Retrospective data
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Imfinzi (durvalumab)
10ms
What value does ctDNA have for monitoring pts with resected #EGFR NSCLC? Report @JTOonline of 278 pts with resected stage I-IIIA EGFR mutant NSCLC (2015-2017) who had longitudinal ddPCR: 24% positive pre-op (42% of IIIA): 76% of those clear after surgery. https://t.co/mrTUvA0Ar6 (@StephenVLiu)
10 months ago
Clinical • Surgery • Circulating tumor DNA
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
10ms
Abstract LBA9000: Pemetrexed and platinum +/- pembrolizumab for TKI-resistant, EGFR-mutant, metastatic nonsquamous NSCLC (KEYNOTE-789) by James CH Yang. Well-powered but "MARGINALLY" negative like CheckMate 722. No durable response even in ICI responders. #ASCO23 #LCSM (@HHorinouchi)
10 months ago
Late-breaking abstract • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Keytruda (pembrolizumab) • pemetrexed
10ms
Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC) [2023] @DrRoyHerbstYale et al. #ASCO23 LBA3 https://t.co/XvquwuG39L #lcsm #PrecisionMedicine (@mtmdphd)
10 months ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Tagrisso (osimertinib)
10ms
From #ASCO23, Thomas John discusses the results from the ADAURA study of adjuvant osimertinib in patients with resected EGFR mutated stage IB–IIIA non-small cell lung cancer. https://t.co/hXAY1yGMnj @TommyJohn00 #NSCLC #EGFRm #LCSM (@myESMO)
10 months ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Tagrisso (osimertinib)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login